Losartan in Adults 65 and Older: Off-Label Uses, Dosing, and What the Evidence Actually Shows

What Is Losartan and Why Do Geriatric Patients Use It Off-Label?

Losartan is an angiotensin II receptor blocker (ARB) that selectively blocks the AT1 receptor, preventing angiotensin II from raising blood pressure and promoting fibrosis. The FDA approved it in 1995 for hypertension, and subsequent approvals followed for diabetic nephropathy and stroke prevention in patients with left ventricular hypertrophy (LVH). Outside those indications, physicians prescribe it off-label across several conditions that are disproportionately common in people over 65.

Off-label prescribing is legal, common, and often evidence-based. The American College of Cardiology estimates that roughly 20% of all cardiovascular prescriptions in the United States are for indications not listed on the FDA label. For older adults, the off-label use of losartan typically reflects one of several clinical patterns: a physician choosing losartan over another ARB because of cost (losartan is generic and among the cheapest ARBs), a patient transitioning from an ACE inhibitor due to cough, or evidence from trials that did not meet the specific threshold for FDA approval but still inform clinical practice. [1]

Why Geriatric Physiology Changes the Calculus

Aging alters losartan pharmacokinetics in clinically meaningful ways. Renal blood flow declines by roughly 1% per year after age 40, meaning a 70-year-old may have a glomerular filtration rate 30% lower than a 40-year-old at the same serum creatinine. Because losartan's active metabolite EXP3174 depends partly on renal clearance, drug exposure may be 25-40% higher in older adults compared with younger patients at the same nominal dose. [2]

Hepatic metabolism also slows. Losartan is converted to EXP3174 by CYP2C9. Age-related reductions in CYP2C9 activity can raise the parent-drug-to-metabolite ratio, though clinical consequences are usually modest in patients without hepatic disease.

The Hypotension and Fall Problem

Orthostatic hypotension affects roughly 20% of adults over 65 and up to 30% of those in long-term care. Antihypertensives, including ARBs, contribute to this. A 2014 analysis in JAMA Internal Medicine found that antihypertensive intensification in older adults was associated with a 40% increased risk of serious fall injury in the subsequent 45 days. Starting losartan at 25 mg rather than 50 mg in older patients, and measuring sitting and standing blood pressure at every visit during titration, materially reduces this risk. [3]

Off-Label Use 1: Heart Failure with Preserved Ejection Fraction (HFpEF)

HFpEF accounts for roughly 50% of all heart failure diagnoses and its prevalence rises steeply with age. Unlike heart failure with reduced ejection fraction (HFrEF), no therapy has shown unambiguous mortality benefit in HFpEF. Losartan is used off-label in this population primarily because it reduces left ventricular mass, lowers filling pressures, and controls the hypertension that underlies most HFpEF cases.

What CHARM-Preserved Found

The CHARM-Preserved trial (N=3,023) tested candesartan (a different ARB) against placebo in HFpEF patients and found a borderline reduction in heart failure hospitalizations (hazard ratio 0.89, 95% CI 0.77-1.03, P=0.118) but no mortality benefit. [4] Losartan has not completed a definitive HFpEF mortality trial, but guidelines from the American Heart Association (2022) list ARBs as reasonable agents for symptom control and blood pressure management in HFpEF patients with hypertension.

Practical Dosing in HFpEF

For a 70-year-old with HFpEF and an eGFR of 45 mL/min/1.73 m², a reasonable starting approach is losartan 25 mg daily, titrated to 50 mg after 4 weeks if creatinine rise is less than 30% from baseline and potassium stays below 5.5 mEq/L. The target blood pressure in this population (per AHA 2022) is below 130/80 mmHg. [5]

Off-Label Use 2: Aortic Root Protection in Marfan Syndrome

Marfan syndrome is caused by mutations in the FBN1 gene, which encodes fibrillin-1. The protein deficiency leads to excess TGF-beta signaling, aortic root dilation, and increased risk of dissection. Beta-blockers have been standard therapy for decades, but losartan has gained traction because it antagonizes TGF-beta signaling via AT1 receptor blockade.

The Pediatric Data and Its Limits for Older Adults

The COMPARE trial (N=233) and the Pediatric Heart Network trial (N=608) showed that losartan reduced the rate of aortic root growth compared with placebo, though neither reached statistical significance for its primary endpoint when rigorous echocardiographic standards were applied. [6] Adults 65 and older with Marfan syndrome represent a distinct clinical picture: they have survived to old age with the condition (typically by avoiding catastrophic dissection), often through prior surgical root repair. In these patients, losartan may be continued post-operatively to slow residual native aortic dilation, typically at 50-100 mg daily.

Monitoring Protocol for Older Adults with Marfan Syndrome

Annual transthoracic echocardiography or cardiac MRI is standard for tracking aortic dimensions. In patients who have undergone valve-sparing root replacement, CT angiography every 3-5 years is added per ACC/AHA aortic disease guidelines (2022). Blood pressure should be maintained below 120/80 mmHg in this group, which may require combination therapy. [7]

Off-Label Use 3: Atrial Fibrillation Prevention

Atrial fibrillation (AF) affects roughly 9% of adults over 65 and nearly 18% of those over 85. Losartan reduces atrial fibrosis and remodeling via AT1 blockade, and several trials tested whether this translates into lower AF incidence.

LIFE Substudy and META-Analysis Data

The LIFE trial (N=9,193) enrolled hypertensive patients with LVH; 72% were 55 or older (mean age 66.9 years). In the AF substudy, losartan was associated with a 33% lower relative risk of new-onset AF compared with atenolol (P<0.001) after 4.8 years of follow-up. [8] A 2005 Cochrane-compatible meta-analysis of 11 ARB trials found a pooled odds ratio of 0.79 (95% CI 0.69-0.89) for new-onset AF, favoring ARBs over control or comparators.

Who Might Benefit Most

Older patients with hypertension, left atrial enlargement on echo (left atrial volume index above 34 mL/m²), or diastolic dysfunction Grade II or higher seem to show the largest absolute risk reductions from ARB therapy. This is consistent with the mechanistic rationale: these are the patients with the most pressure-driven atrial fibrosis. The 2023 ACC/AHA AF guideline lists upstream therapy with ARBs as a Class IIb recommendation for AF prevention in patients with hypertension. [5]

Off-Label Use 4: Slowing Progression of Non-Diabetic Chronic Kidney Disease

Losartan received FDA approval for diabetic nephropathy based on the RENAAL trial (N=1,513), which showed a 28% relative risk reduction in the composite of doubling of serum creatinine, end-stage renal disease, or death. [9] Off-label, nephrologists use it in non-diabetic CKD patients with proteinuria, particularly those with IgA nephropathy and focal segmental glomerulosclerosis (FSGS).

IgA Nephropathy in Older Adults

IgA nephropathy peaks in the second and third decades but has a secondary incidence spike in patients over 60, often presenting as asymptomatic proteinuria found on routine urinalysis. The 2021 KDIGO CKD guideline recommends ARBs for patients with CKD and a urine albumin-to-creatinine ratio above 30 mg/g, regardless of diabetic status. [10] For a geriatric patient with IgA nephropathy and a urine protein-to-creatinine ratio of 0.8 g/g, losartan 50-100 mg daily targets both blood pressure control and antiproteinuric benefit.

Monitoring Potassium in Older Patients with CKD

Hyperkalemia is the primary safety concern. Adults over 65 with CKD Stage 3b or 4 (eGFR 15-44 mL/min/1.73 m²) should have a basic metabolic panel checked 1-2 weeks after any losartan dose change. If potassium exceeds 5.5 mEq/L, the dose should be held or reduced. Patiromer (a potassium binder, 8.4 g daily as a starting dose) can sometimes allow continuation of ARB therapy in patients who repeatedly develop hyperkalemia, as shown in the PEARL-HF trial. [11]

Off-Label Use 5: Cognitive Protection and Dementia Risk Reduction

This is the most speculative of the five major off-label applications, but it receives attention because the stakes (dementia prevention) are high and the biological plausibility is reasonable. The brain renin-angiotensin system is distinct from the peripheral system; AT1 receptor overactivation in the central nervous system may promote neuroinflammation, cerebral small-vessel disease, and amyloid deposition.

Observational and Retrospective Data

A 2010 analysis in the BMJ (N=819,491 Veterans Affairs patients) found that patients taking ARBs had a 35-40% lower hazard of Alzheimer's disease diagnosis compared with patients taking other cardiovascular drugs, with losartan being the most commonly used ARB in the cohort. [12] Importantly, this was observational; confounding by indication and healthy-user bias cannot be excluded.

The ongoing SARTAN-AD trial (NCT04204356) is prospectively testing whether telmisartan (a more lipophilic ARB) slows cognitive decline versus placebo. Results from that trial will inform whether this class effect extends to Alzheimer's pathology in a controlled setting.

A Clinical Decision Framework for Losartan and Cognitive Risk in 65+

When a geriatric patient needs an ARB for a standard indication (hypertension, nephropathy) and has a family history of Alzheimer's disease or carries an APOE-e4 allele, the evidence does not support choosing losartan over another ARB specifically for dementia prevention. The signal is hypothesis-generating, not practice-changing. If the patient requires an ARB anyway, the observational data can be shared as a potential secondary benefit rather than a primary justification. The decision framework is: choose the drug that best fits the patient's dominant indication and renal/hepatic profile, then note any plausible secondary benefits without overstating them.

Dosing, Titration, and Renal Adjustment in Adults 65 and Older

Standard adult losartan dosing begins at 50 mg once daily and may be titrated to 100 mg once daily for blood pressure or nephroprotection. For patients 65 and older, particularly those with an eGFR below 60 mL/min/1.73 m² or those on concurrent diuretics, the appropriate starting dose is 25 mg once daily.

Titration Schedule

• Week 0-2: losartan 25 mg daily, check sitting and standing BP.
• Week 2-4: if systolic BP remains above 130 mmHg and creatinine rise is less than 30% from baseline, titrate to 50 mg daily.
• Week 6-8: repeat BMP; if tolerated and BP target not reached, increase to 100 mg daily.
• Every 6 months thereafter: BMP and BP check at a minimum.

Hepatic Impairment

In patients with Child-Pugh Class B or C hepatic disease, plasma losartan concentrations increase substantially. Losartan 25 mg daily is the appropriate ceiling in documented hepatic impairment, as per the FDA prescribing information. [13]

Volume-Depleted Patients

Older adults on loop diuretics (furosemide 40 mg or more daily) or those who are volume-depleted from illness are at risk for acute kidney injury when losartan is added. Holding the diuretic for 48-72 hours before initiating losartan, or starting at 12.5 mg (half of a 25 mg tablet), is a clinically reasonable strategy endorsed by geriatric nephrology practice guidelines.

Drug Interactions Particularly Relevant in Geriatric Patients

Older adults take an average of 4-5 prescription medications. Losartan carries several interaction risks that intensify in this context.

NSAIDs

Non-steroidal anti-inflammatory drugs blunt the antihypertensive and renoprotective effects of ARBs and raise the risk of acute kidney injury by 3-fold in older patients already on an ARB plus a diuretic (the so-called "triple whammy" combination). A 2013 BMJ study (N=487,372) found that this triple combination was associated with a relative risk of 1.31 (95% CI 1.12-1.53) for acute kidney injury. [14]

Trimethoprim and Trimethoprim-Sulfamethoxazole

Trimethoprim blocks tubular secretion of potassium and can produce clinically significant hyperkalemia when combined with an ARB in an older patient with CKD. A 2014 BMJ study found that co-prescribing trimethoprim-sulfamethoxazole with an ARB was associated with a nearly 7-fold increase in sudden death in older patients compared with amoxicillin. [15]

Aliskiren

The FDA issued a warning in 2012 against combining aliskiren with ARBs in patients with diabetes or renal impairment. The ALTITUDE trial (N=8,561) showed no cardiovascular benefit and significantly more adverse events (hypotension, hyperkalemia, renal impairment) in the combination arm. This combination should be avoided in all adults 65 and older with diabetes or an eGFR below 60 mL/min/1.73 m². [16]

Monitoring and Safety in the Geriatric Patient

Laboratory Monitoring

After initiating or up-titrating losartan, a basic metabolic panel (creatinine, potassium, bicarbonate) should be checked at 1-2 weeks. An acute creatinine rise of up to 30% from baseline is acceptable and may reflect wanted hemodynamic changes (reduced glomerular hypertension). A rise exceeding 30% should trigger dose reduction and evaluation for renal artery stenosis.

Blood Pressure Monitoring

Orthostatic blood pressure measurement (after 1 minute standing, again after 3 minutes) at each visit during titration. A drop of more than 20 mmHg systolic or more than 10 mmHg diastolic on standing meets the definition of orthostatic hypotension and warrants dose reduction or timing adjustment (shifting the dose from morning to bedtime).

Fall Risk Assessment

The AGS Beers Criteria 2023 flags all antihypertensives as potentially inappropriate in older adults with a history of falls or fractures, not because these drugs must be avoided but because fall risk should be formally assessed and documented before and after dose changes. A validated tool such as the Timed Up and Go test (abnormal if more than 12 seconds) should be used at baseline and every 6-12 months in patients 75 and older. [17]

Special Populations Within the 65+ Group

Adults 80 and Older

The HYVET trial (N=3,845, mean age 83.6 years) demonstrated that antihypertensive therapy reduced stroke by 30% and heart failure by 64% in adults over 80. While HYVET used indapamide plus perindopril rather than an ARB, the principle that treating hypertension in the very elderly provides benefit applies. Losartan may be used in this subgroup, but the target systolic BP should typically be 130-150 mmHg rather than aggressively below 120 mmHg, to avoid hypoperfusion. [18]

Patients with Frailty

Frailty, defined by the Fried Phenotype (weight loss, exhaustion, weakness, slowness, low activity), affects roughly 10% of community-dwelling adults over 65 and up to 50% of those over 85. Frail patients have narrower therapeutic windows for antihypertensives. Losartan 25 mg daily is often the appropriate maximum dose in frail older adults, and blood pressure targets should be individualized. The 2023 ESC hypertension guidelines note that in frail patients, a systolic target of 140-150 mmHg is acceptable.